Abcuro
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
55 Chapel St Ste 200, Newton, Massachuse...Phone Number
(617) 714-9759Website
www.abcuro.comRevenue
$6.3 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
4
2
1
1
1
1
About Abcuro
Abcuro is a clinical stage biotechnology company developing first-in-class immunotherapies for the treatment of autoimmune diseases and cancer through precise modulation of highly cytotoxic T cells. The companys lead program is ulviprubart (ABC008) and is currently in clinical trials for inclusion body myositis (IBM) and T cell large granular lymphocytic leukemia.Explore more
Abcuro Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Abcuro your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Abcuro recently announced quarterly report
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Abcuro
Click to see if Abcuro had a recent Job posting/layoffs
Product Launch: Get notified when Abcuro launches new products
Check if Abcuro has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Abcuro has new funding data
Abcuro, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Abcuro is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Abcuro
Compare insights from companies similar to Abcuro, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Abcuro is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Abcuro is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Abcuro.
Abcuro financials insights
Gather financial insights about Abcuro, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$50M
2023
Series B
$155M
2025
Series C
$200M
Abcuro Tech Stack
A closer look at the technologies used by Abcuro
See more technologies
Most Recent Scoops
Person-Based
Medical Research, Clinical Operations
Person-Based
Pharmaceuticals, Clinical Operations
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
Open Position
Abcuro News & Media
Abcuro Appoints Courtney Cupples as Chief Commercial Officer
NEWTON, Mass.--(BUSINESS WIRE)--Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced the appointment of Courtney Cupples as Chief Commercial Officer (CCO). Ms. Cupples brings more than 25 years of global commercial leadership and rare disease product launch experience. “We are excited to welcome Courtney to Abcuro as a key member of the leadership team as weFoley Represents NEA as Lead Investor in $200M Series C Round for Abcuro
Foley & Lardner LLP represented New Enterprise Associates (NEA) as the lead investor in the $200 million Series C financing for Abcuro, a clinical-stage biotechnology company.Abcuro to Present Two Posters at the American Academy of Neurology 2025 Annual Meeting
NEWTON, Mass.--(BUSINESS WIRE)--Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced that the Company will present safety, pharmacokinetic, and pharmacodynamic data from the Phase 1 clinical trial evaluating ulviprubart (ABC008) for the treatment of inclusion body myositis (IBM) at the American Academy of Neurology (AAN) Annual Meeting, taking place April 5-9
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Abcuro
Sign Up For FreeTo access detailed company insights
Abcuro is a clinical stage biotechnology company developing first-in-class immunotherapies for the treatment of autoimmune diseases and cancer through precise modulation of highly cytotoxic T cells. The companys lead program is ulviprubart (ABC008) and is currently in clinical trials for inclusion body myositis (IBM) and T cell large granular lymph... Read More
